Saturday, October 3, 2026

CBOE Went Down By Over 6% In The Last 24 Hours

ViaNews Editorial Team

February 14, 2023

CBOE Went Down By Over 6% In The Last 24 Hours

(VIANEWS) - CBOE (VIX) has been up by 6.14% for the last session's close. At 09:08 EST on Tuesday, 14 February, CBOE (VIX) is $19.27.

CBOE Range

About CBOE's daily highs and lows, it's 5.21% down from its trailing 24 hours low of $20.33 and 11.16% down from its trailing 24 hours high of $21.69.

Concerning CBOE's yearly highs and lows, it's 12.95% up from its 52-week low and 49.01% down from its 52-week high.

Volatility

CBOE's last week, last month's, and last quarter's current intraday variation average was 2.22%, 0.54%, and 4.25%, respectively.

CBOE's highest amplitude of average volatility was 3.13% (last week), 3.53% (last month), and 4.25% (last quarter), respectively.

News about

  • According to FXStreet on Monday, 13 February, "While portraying the mood, the S&P 500 Futures fade the previous day's corrective bounce off a one-week low, down 0.50% around 4,080 at the latest, whereas the US 10-year Treasury yields remain sidelined near 3.73% after refreshing a five-week high the previous day."
  • According to MarketWatch on Monday, 13 February, "Based on Friday's stock closing price of $17.08, the new annual dividend rate implies a dividend yield of 2.34%, which compares with the yield for the SPDR S&P Regional Banking exchange-traded fund of 2.34% and the implied yield for the S&P 500 of 1.66%. ", "The stock has edged up 0.1% over the past three months while the regional bank ETF has slipped 3.1% and the S&P 500 has gained 2.4%."
  • According to MarketWatch on Monday, 13 February, "Axsome's stock has gained 95.8% over the past year, while the S&P 500 declined 7.6%."
  • According to FXStreet on Monday, 13 February, "While portraying the mood, the S&P 500 Futures fade the previous day's corrective bounce off a one-week low, down 0.35% around 4,080 at the latest, whereas the US 10-year Treasury yields remain sidelined near 3.73% after refreshing a five-week high on Friday."
  • According to FXStreet on Monday, 13 February, "Amid these plays, the S&P 500 Futures fade the previous day's corrective bounce off a one-week low, down 0.35% around 4,080 at the latest, whereas the US 10-year Treasury yields remain sidelined near 3.73% after refreshing a five-week high on Friday. "

More news about CBOE (VIX).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com